Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2017 | 1 |
2018 | 1 |
2019 | 1 |
2021 | 1 |
2024 | 0 |
Search Results
4 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial.
Lancet Oncol. 2021 Apr;22(4):463-475. doi: 10.1016/S1470-2045(20)30755-5. Epub 2021 Mar 5.
Lancet Oncol. 2021.
PMID: 33684370
Clinical Trial.
Successful treatment with trastuzumab in HER2-positive squamous cell carcinoma of the head and neck.
Saleh K, Saada E, Auger N, Mayache-Badis L, Casiraghi O, Bidault F, Bahleda R, Even C.
Saleh K, et al. Among authors: mayache badis l.
Oral Oncol. 2019 Apr;91:129-131. doi: 10.1016/j.oraloncology.2019.02.008. Epub 2019 Feb 14.
Oral Oncol. 2019.
PMID: 30773349
No abstract available.
Item in Clipboard
High incidence of cetuximab-related infusion reactions in head and neck patients.
Palomar Coloma V, Bravo P, Lezghed N, Mayache-Badis L, Herrera Gómez RG, Iacob M, Nicouleau L, Desmaris R, Tao Y, Leibu C, Matias M, Lemare F, Even C, Annereau M, Ferté C.
Palomar Coloma V, et al. Among authors: mayache badis l.
ESMO Open. 2018 Jul 23;3(5):e000346. doi: 10.1136/esmoopen-2018-000346. eCollection 2018.
ESMO Open. 2018.
PMID: 30094066
Free PMC article.
Item in Clipboard
Long-term response in patient with recurrent oropharyngeal carcinoma treated with cetuximab, docetaxel and cisplatin (TPEx) as first-line treatment followed by cetuximab maintenance.
Guigay J, Even C, Mayache-Badis L, Debbah M, Saada-Bouzid E, Tao Y, Deschamps F, Janot F, Lezghed N, Michel C.
Guigay J, et al. Among authors: mayache badis l.
Oral Oncol. 2017 May;68:114-118. doi: 10.1016/j.oraloncology.2017.03.009. Epub 2017 Mar 24.
Oral Oncol. 2017.
PMID: 28347701
Item in Clipboard
Cite
Cite